In rodent models, direct deletion of MMR genes, such as MLH130 or MSH231, in tumours triggers neoantigen generation and cytotoxic T cell infiltration, impairs tumour growth, and sensitises them to ICB therapies. Here, MRC1 is linked to neoplasm.